Are you interested in a language intervention that may help your child with Fragile X Syndrome communicate better?

Dr. Elizabeth Berry-Kravis at Rush University is the Protocol Principal Investigator and is leading a national study, NN107 FX-LEARN. There are two purposes to the study. First, to find out if the drug AFQ056, made by the pharmaceutical company Novartis, is safe and has beneficial effects on learning in children who have Fragile X syndrome (FXS).  Second, to find out if a structured language intervention can help children with Fragile X syndrome communicate better.

The trial will be a multi-center, phase II randomized, double-blind placebo-controlled parallel-group flexible-dose forced-titration study that will use a novel design to address the impact of AFQ056 on language learning in 3- to 6-year-old children with FXS. Subjects will be in the study a total of 21 months (Screening and 12 months placebo-controlled treatment, 8 months open-label extension, 1 month follow up after final assessment visit). The study is conducted by the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). The National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH), is supporting this trial.

Q: Who can participate?

Children ages 3-6:

  • With Fragile X Syndrome.
  • Who use intentional acts of communication (including words, gestures, and augmentative communication devices).

Q: What does the study involve?

  • 15 study visits over 21 months.
  • Behavioral and language assessments, medical history, a physical exam, parent questionnaires, and blood and urine sampling.
  • Weekly video conferencing sessions in your home to learn strategies to help your child with language.
  • Child will be randomized to either AFQ056 or placebo.

Q: What else can I expect?

  • Families receive instruction and feedback from expert speech and language pathologists.
  • Travel reimbursement is available.
  • Also, check out Diane and her son Joshua’s experience with this trial:

Q: How can I learn more before applying?

NFXF FX-LEARN Q&A Webinar with Dr. Berry-Kravis

Q: Where can I participate?

  • The following clinical sites are currently enrolling participants. Use the contact form on this page to be connected with the coordinator, Katie Friedmann, RN, who will work to get you enrolled, if eligible, at the most convenient and available site.
Boston Children’s HospitalUniversity of Cincinnati Medical Center
Children’s Hospital of Philadelphia University of Colorado – Denver
Children’s National Medical Center (DC)University of Pittsburgh
Columbia University Medical Center (NY)University of Texas Soutdwestern Medical Center
Emory University (GA)Vanderbilt University (TN)
Nationwide Children’s Hospital (OH)Washington University in Saint Louis
Rush University (IL)Yale University (CT)
University of California at Davis

If you’d like to learn more or apply for this opportunity, please fill out the form to send your contact information to the study coordinators.

If you arrived on this page through a MyFXResearch Portal search, you can close this window and return to your filtered results. Or start a new search here.
View More Opportunities

Parent Survey: Children’s Behavioral Strengths and Challenges

The MIND Group at the University of Minnesota is conducting a survey for parents of children with Fragile X syndrome to learn about how genetic and neurodevelopmental differences impact behavioral strengths and challenges. Parents of 3–17 year old children living with Fragile X are eligible to participate.

Study: Language Environment Analysis Project (LEAP)

Purdue University is conducting a research study to learn about language and social communication development in Fragile X syndrome. Children ages 3–4 years (36–60 months) with the full mutation may be eligible to participate.

Purdue Early Childhood Study – PANDABox

Purdue University is conducting a research study to learn about development of infants with Fragile X syndrome. Boys and girls ages 6-18 months with the full mutation may be eligible to participate.

Fragile X Premutation Carrier Study at University of Kansas

The University of Kansas BRAIN Lab is conducting a research study to learn about behavioral and brain differences associated with premutations of the Fragile X gene, FMR1. Individuals ages 50–80 with the FMR1 gene premutation with or without FXTAS may be eligible to participate.